Sector: Financials | Industry: Investment Management & Fund Operators |
Company Contact | |
Address: | 191 The West Mall, Suite 905 TORONTO ON M9C 5L6 |
Tel: | 1-416-6953393 |
Website: | https://www.nexgenrx.com |
IR: | See website |
Key People | ||
Ronald C. Loucks President, Chief Executive Officer, Director | Kelly Ehler Chief Financial Officer | Andrew Munroe Senior Vice President - Pharma and Payor Partners |
Business Overview |
NexgenRx Inc. is a Canada-based third-party administrator and technology solutions provider. The Company is focused on building technology platforms that equip its clients with unprecedented capabilities for managing and self-managing group benefit plans, group pension plans and patient support programs. The Company offers plan sponsors, administration and health benefit technology applications in a of software-as-a-service model. The Company's products include NexSys, NexAdmin, NexPension and NexPSPAssist. The NexSys product platform provides solution and simplifies adjudication of dental, prescription drug and extended health claims. Its NexAdmin product enables sponsors to take complete control of benefit plan administration. Its NexPension product is an advanced pension administration solution designed to help sponsors record and tabulate contributions for their membership group in a multi-employer environment. Its platform makes self-administration a reality. |
Financial Overview |
For the nine months ended 30 September 2023, NexgenRx Inc revenues increased 9% to C$10.3M. Net income decreased 84% to C$56K. Revenues reflect Administration fees increase of 40% to C$4.7M, Other Income increase from C$109K to C$391K, Consulting increase of 12% to C$1.2M. Net income was offset by Compensation and external contractors increase of 16% to C$5.7M (expense), Professional fees increase of 21% to C$265K (expense). |
Employees: | 20 as of Mar 31, 2006 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $17.34M as of Sep 30, 2023 |
Annual revenue (TTM): | $13.65M as of Sep 30, 2023 |
EBITDA (TTM): | $1.17M as of Sep 30, 2023 |
Net annual income (TTM): | -$0.31M as of Sep 30, 2023 |
Free cash flow (TTM): | $0.15M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 70,921,820 as of Mar 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |